NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
26 avr. 2023 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune...
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
28 mars 2023 16h01 HE
|
NexImmune, Inc.
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to...
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
16 févr. 2023 07h00 HE
|
NexImmune, Inc.
Tumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naïve CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in...
NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases
18 janv. 2023 16h01 HE
|
NexImmune, Inc.
AIM technology represents a scalable therapeutic platform that has the potential to create new, multi-antigen specific therapies for virally driven infectious diseases, cancers and autoimmune diseases...
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
14 nov. 2022 16h01 HE
|
NexImmune, Inc.
Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate...
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
06 oct. 2022 07h00 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Oct. 06, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09 sept. 2022 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers
15 août 2022 16h05 HE
|
NexImmune, Inc.
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related...
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
14 juil. 2022 16h09 HE
|
NexImmune, Inc.
First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product...
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
12 mai 2022 16h01 HE
|
NexImmune, Inc.
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND) submission for NEXI-003, the Company’s first product...